Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

SARS-CoV-2 RBD-Tetanus Toxoid Conjugate Vaccine Induces a Strong Neutralizing Immunity in Preclinical Studies
Yury Valdés-Balbín, Darielys Santana-Mederos, Lauren Quintero, et al.
ACS Chemical Biology (2021) Vol. 16, Iss. 7, pp. 1223-1233
Open Access | Times Cited: 80

Showing 1-25 of 80 citing articles:

A Comprehensive Review of the Protein Subunit Vaccines Against COVID-19
Mohsen Heidary, Vahab Hassan Kaviar, Maryam Shirani, et al.
Frontiers in Microbiology (2022) Vol. 13
Open Access | Times Cited: 133
Chemical Conjugation Strategies for the Development of Protein-Based Subunit Nanovaccines
Lantian Lu, Viet Tram Duong, Ahmed O. Shalash, et al.
Vaccines (2021) Vol. 9, Iss. 6, pp. 563-563
Open Access | Times Cited: 73
Molecular Aspects Concerning the Use of the SARS-CoV-2 Receptor Binding Domain as a Target for Preventive Vaccines
Yury Valdés-Balbín, Darielys Santana-Mederos, Françoise Paquet, et al.
ACS Central Science (2021) Vol. 7, Iss. 5, pp. 757-767
Open Access | Times Cited: 62
Safety and efficacy of the two doses conjugated protein-based SOBERANA-02 COVID-19 vaccine and of a heterologous three-dose combination with SOBERANA-Plus: a double-blind, randomised, placebo-controlled phase 3 clinical trial
María Eugenia Toledo-Romaní, Mayra García-Carmenate, Carmen Valenzuela‐Silva, et al.
The Lancet Regional Health - Americas (2022) Vol. 18, pp. 100423-100423
Open Access | Times Cited: 39
COVID-19 Vaccines: Where Did We Stand at the End of 2023?
Kenneth Lundström
Viruses (2024) Vol. 16, Iss. 2, pp. 203-203
Open Access | Times Cited: 10
RBD-displaying OMV nanovaccine boosts immunity against SARS-CoV-2
Rang Feng, Ruo‐Yi Xue, Chang Liu, et al.
Journal of Nanobiotechnology (2025) Vol. 23, Iss. 1
Open Access | Times Cited: 1
Safety and immunogenicity of anti-SARS CoV-2 vaccine SOBERANA 02 in homologous or heterologous scheme: Open label phase I and phase IIa clinical trials
María Eugenia-Toledo-Romaní, Leslyhana Verdecia-Sánchez, Meiby Rodríguez-González, et al.
Vaccine (2022) Vol. 40, Iss. 31, pp. 4220-4230
Open Access | Times Cited: 34
Efficacy and Safety of a Protein-Based SARS-CoV-2 Vaccine
Ehsan Mostafavi, Sana Eybpoosh, Mohammad Karamouzian, et al.
JAMA Network Open (2023) Vol. 6, Iss. 5, pp. e2310302-e2310302
Open Access | Times Cited: 21
Nanocarrier vaccine therapeutics for global infectious and chronic diseases
Faizan Zarreen Simnani, Dibyangshee Singh, Paritosh Patel, et al.
Materials Today (2023) Vol. 66, pp. 371-408
Open Access | Times Cited: 20
CHO cells for virus-like particle and subunit vaccine manufacturing
Zalma V. Sanchez-Martinez, Sergio P. Alpuche-Lazcano, Matthew Stuible, et al.
Vaccine (2024) Vol. 42, Iss. 10, pp. 2530-2542
Open Access | Times Cited: 6
COVID-19 Vaccinations: A Comprehensive Review of Their Safety and Efficacy in Special Populations
Zhipeng Yan, Ming Yang, Ching‐Lung Lai
Vaccines (2021) Vol. 9, Iss. 10, pp. 1097-1097
Open Access | Times Cited: 39
Safety and immunogenicity of anti-SARS-CoV-2 heterologous scheme with SOBERANA 02 and SOBERANA Plus vaccines: Phase IIb clinical trial in adults
María Eugenia Toledo-Romaní, Mayra García-Carmenate, Leslyhana Verdecia-Sánchez, et al.
Med (2022) Vol. 3, Iss. 11, pp. 760-773.e5
Open Access | Times Cited: 26
Elucidating the Effect of Nanoscale Receptor-Binding Domain Organization on SARS-CoV-2 Infection and Immunity Activation with DNA Origami
Jialü Zhang, Yunyun Xu, Mingying Chen, et al.
Journal of the American Chemical Society (2022) Vol. 144, Iss. 46, pp. 21295-21303
Closed Access | Times Cited: 22
Open-label phase I/II clinical trial of SARS-CoV-2 receptor binding domain-tetanus toxoid conjugate vaccine (FINLAY-FR-2) in combination with receptor binding domain-protein vaccine (FINLAY-FR-1A) in children
Rinaldo Puga-Gómez, Yariset Ricardo-Delgado, Chaumey Rojas-Iriarte, et al.
International Journal of Infectious Diseases (2022) Vol. 126, pp. 164-173
Open Access | Times Cited: 19
Role of N343 glycosylation on the SARS-CoV-2 S RBD structure and co-receptor binding across variants of concern
Callum M. Ives, Linh Nguyen, Carl A. Fogarty, et al.
eLife (2024) Vol. 13
Open Access | Times Cited: 4
On the utility of the extracted ion chromatograms for assigning the conjugation sites and side reactions in bioconjugates synthesized by the maleimide-thiol chemistry
Satomy Pousa, Pablo E. Ramos‐Bermúdez, Vladimir Besada, et al.
Microchemical Journal (2024) Vol. 204, pp. 111025-111025
Closed Access | Times Cited: 4
Immunobiology and immunotherapy of COVID-19
Kenneth Lundström
Progress in molecular biology and translational science (2025)
Closed Access
SARS-CoV-2 conjugate vaccine elicits robust immune responses that can protect against evolving variants.
Melanie L. Carroll, Heather Fox, Anh Tran, et al.
Vaccine (2025) Vol. 54, pp. 126988-126988
Open Access
Immune Evasive Effects of SARS-CoV-2 Variants to COVID-19 Emergency Used Vaccines
Yandi Zhang, Jo‐Lewis Banga Ndzouboukou, Mengze Gan, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 25
A Novel Bacterial Protease Inhibitor Adjuvant in RBD-Based COVID-19 Vaccine Formulations Containing Alum Increases Neutralizing Antibodies, Specific Germinal Center B Cells and Confers Protection Against SARS-CoV-2 Infection in Mice
Lorena M. Coria, Lucas Saposnik, Celeste Pueblas Castro, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 17
Structure Guided Design of Bacteriophage Qβ Mutants as Next Generation Carriers for Conjugate Vaccines
Suttipun Sungsuwan, Xuanjun Wu, Vincent Shaw, et al.
ACS Chemical Biology (2022) Vol. 17, Iss. 11, pp. 3047-3058
Open Access | Times Cited: 16
Recombinant Protein Vaccines against Human Betacoronaviruses: Strategies, Approaches and Progress
Angelina Kovalenko, Ekaterina M. Ryabchevskaya, Ekaterina A. Evtushenko, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 2, pp. 1701-1701
Open Access | Times Cited: 9
N-propionyl thiosuccinimide linker upon hydrolysis becomes into a cleavable crosslinker by a gas phase metastable fragmentation and makes more reliable the conjugation sites identification.
Luis Javier González, Pablo E. Ramos‐Bermúdez, Satomy Pousa, et al.
(2024)
Open Access | Times Cited: 3
Real-world effectiveness of the heterologous SOBERANA-02 and SOBERANA-Plus vaccine scheme in 2–11 years-old children during the SARS-CoV-2 Omicron wave in Cuba: a longitudinal case-population study
María Eugenia Toledo-Romaní, Carmen Valenzuela‐Silva, Minerva Montero-Díaz, et al.
The Lancet Regional Health - Americas (2024) Vol. 34, pp. 100750-100750
Open Access | Times Cited: 3
A COVID-19 vaccine candidate composed of the SARS-CoV-2 RBD dimer and Neisseria meningitidis outer membrane vesicles
Darielys Santana-Mederos, Rocmira Pérez-Nicado, Yanet Climent-Ruíz, et al.
RSC Chemical Biology (2021) Vol. 3, Iss. 2, pp. 242-249
Open Access | Times Cited: 22
Page 1 - Next Page

Scroll to top